<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02474654</url>
  </required_header>
  <id_info>
    <org_study_id>15-009</org_study_id>
    <nct_id>NCT02474654</nct_id>
  </id_info>
  <brief_title>Implementation of a Pain Management Protocol for Total Knee Arthroplasty</brief_title>
  <official_title>An Analysis of the Functional Benefit, Narcotic Use and Time to Discharge Readiness Following the Implementation of a Comprehensive Pain Management Protocol for Primary Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Health Sciences North Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Health Sciences North Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study question: Is there an ideal combination of intraoperative long acting analgesics
      (periarticular infiltration (PI), femoral nerve block (FB) and intrathecal opioids (IO)) to
      optimize post-operative functional recovery, decrease overall narcotic consumption and enable
      faster 'readiness to discharge' for patients undergoing primary total knee replacement (TKR)?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our study design is a five-arm double blinded randomized control trial. In order to create a
      blinded study, each participant will have all three interventions (Femoral Nerve Block (FB),
      Periarticular Injection (PI) and Intrathecal Opioid (IO)) performed during their visit.
      Normal saline (NS) will be substituted for opioid or local anesthetic in cases where a
      control is required.

      Specific 5 arms include:

        -  Using all three anesthetics:

           o PI + FB + IO (arm 1)

        -  Using a combination of two anesthetics + normal saline substitute for control:

             -  NS + FB + IO (arm 2)

             -  PI + NS + IO (arm 3)

             -  PI + FB + NS (arm 4)

        -  Control:

             -  NS + NS + IO (arm 5)

      The control arm would include IO as the sole intervention as this is simply added to the
      spinal anesthetic used for the surgery itself. It is felt that having a study arm without any
      long-acting analgesic medication (opioid or local anesthetic) as the &quot;control&quot; arm following
      a spinal anesthetic would not meet current standard of care and cause harm to the participant

      The investigators hypothesize that the combination of three forms of long acting analgesia
      (PI, FB, IO) will result in the greatest outcomes compared to a combination of any two or
      control. Our aim is to demonstrate that this optimal analgesic combination will have an
      additive pain control effect and will minimize side effects thus translating to less acute
      pain, improve patient mobility, and attaining &quot;readiness to discharge&quot; quicker.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">January 14, 2019</completion_date>
  <primary_completion_date type="Actual">January 14, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Discharge</measure>
    <time_frame>Post-op day 1 to discharge date or day 5</time_frame>
    <description>Meeting discharge criteria - Participants will be followed for the duration of hospital stay, approximately 3-5 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time up and go performance measures</measure>
    <time_frame>Post-op day1 to discharge date or day 5</time_frame>
    <description>Measured by physiotherapists - Functional Outcome - Participants will be followed for the duration of hospital stay, approximately 3-5 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Opioid Consumption Measures</measure>
    <time_frame>Post-op day 0 to discharge date or day 5</time_frame>
    <description>Narcotic Use and Assessment - Participants will be followed for the duration of hospital stay, approximately 3-5 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>Post-op day 0 to discharge date or day 5</time_frame>
    <description>To include nausea, vomiting, pruritis as assessed by Common Terminology Criteria for Adverse Events (CTCAE) - Participants will be followed for the duration of hospital stay, approximately 3-5 days</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Knee Replacement, Total</condition>
  <arm_group>
    <arm_group_label>Arm 1: PI+FNB+IO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, 0.5% Ropivicaine with 1:400,000 Epinephrine 30ml, Ropivicaine 100ml, Epinephrine 600mcg, Ketorolac 30mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2:NS+FNB+IO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, 0.5% Ropivicaine with1:400,000 Epinephrine 30ml, Normal Saline 100ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: PI+NS+IO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, Normal Saline 30ml, Ropivicaine 100ml, Epinephrine 600mcg, Ketorolac 30mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: PI+FNB+NS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bupivicaine 15mg, Fentanyl 15mcg, Normal Saline 0.3ml, 0.5% Ropivicaine with 1:400,000 Epinephrine 30ml, Ropivicaine 100ml, Epinephrine 600mcg, Ketorolac 30mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5:NS+NS+IO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, Normal Saline 30ml, Normal Saline 100ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivicaine</intervention_name>
    <description>15mg</description>
    <arm_group_label>Arm 1: PI+FNB+IO</arm_group_label>
    <arm_group_label>Arm 2:NS+FNB+IO</arm_group_label>
    <arm_group_label>Arm 3: PI+NS+IO</arm_group_label>
    <arm_group_label>Arm 4: PI+FNB+NS</arm_group_label>
    <arm_group_label>Arm 5:NS+NS+IO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>15mcg</description>
    <arm_group_label>Arm 1: PI+FNB+IO</arm_group_label>
    <arm_group_label>Arm 2:NS+FNB+IO</arm_group_label>
    <arm_group_label>Arm 3: PI+NS+IO</arm_group_label>
    <arm_group_label>Arm 4: PI+FNB+NS</arm_group_label>
    <arm_group_label>Arm 5:NS+NS+IO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epimorphine</intervention_name>
    <description>150mcg</description>
    <arm_group_label>Arm 1: PI+FNB+IO</arm_group_label>
    <arm_group_label>Arm 2:NS+FNB+IO</arm_group_label>
    <arm_group_label>Arm 3: PI+NS+IO</arm_group_label>
    <arm_group_label>Arm 5:NS+NS+IO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>0.3 ml</description>
    <arm_group_label>Arm 4: PI+FNB+NS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>30ml</description>
    <arm_group_label>Arm 3: PI+NS+IO</arm_group_label>
    <arm_group_label>Arm 5:NS+NS+IO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>100 ml</description>
    <arm_group_label>Arm 2:NS+FNB+IO</arm_group_label>
    <arm_group_label>Arm 5:NS+NS+IO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivicaine</intervention_name>
    <description>100 ml</description>
    <arm_group_label>Arm 1: PI+FNB+IO</arm_group_label>
    <arm_group_label>Arm 3: PI+NS+IO</arm_group_label>
    <arm_group_label>Arm 4: PI+FNB+NS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine</intervention_name>
    <description>600 mcg</description>
    <arm_group_label>Arm 1: PI+FNB+IO</arm_group_label>
    <arm_group_label>Arm 3: PI+NS+IO</arm_group_label>
    <arm_group_label>Arm 4: PI+FNB+NS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>30 mg</description>
    <arm_group_label>Arm 1: PI+FNB+IO</arm_group_label>
    <arm_group_label>Arm 3: PI+NS+IO</arm_group_label>
    <arm_group_label>Arm 4: PI+FNB+NS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivicaine with Epinephrine</intervention_name>
    <description>0.5% 1:400,000 30ml</description>
    <arm_group_label>Arm 1: PI+FNB+IO</arm_group_label>
    <arm_group_label>Arm 2:NS+FNB+IO</arm_group_label>
    <arm_group_label>Arm 4: PI+FNB+NS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  primary total knee replacement for osteoarthritis

          -  agrees to a spinal anesthetic for TKR

        Exclusion Criteria:

          -  History of chronic pain or opioid tolerance (individuals requiring equivalent of 1 mg
             or more intravenous or 3 mg or more oral morphine per hour for greater than 1 month)

          -  general anesthetic for TKR

          -  major neurological deficit

          -  allergy to local anesthetic

          -  allergy to morphine or hydromorphone, anti-inflammatory, acetaminophen

          -  renal insufficiency

          -  liver failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Wong, MD, FRCPC, BSc, PT</last_name>
    <role>Principal Investigator</role>
    <affiliation>Health Sciences North</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Health Sciences North Research Institute</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 6, 2015</study_first_submitted>
  <study_first_submitted_qc>June 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2015</study_first_posted>
  <last_update_submitted>January 16, 2019</last_update_submitted>
  <last_update_submitted_qc>January 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

